Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL551837 | 0.91 | FFAR1 (0.67) | MAOBFFAR1FFAR4XDH | |
| SCHEMBL1461922 | 0.85 | FFAR1 (0.52) | MAOBFFAR1FFAR4XDH | |
| SCHEMBL448079 | 0.83 | MAOB (0.57) | MAOBXDH | |
| SCHEMBL1330628 | 0.83 | MAOB (0.62) | MAOBXDH | |
| SCHEMBL9706364 | 0.83 | MAOB (0.58) | MAOBFFAR1FFAR4XDH | |
| SCHEMBL31496915 | 0.82 | FFAR1 (0.52) | MAOBFFAR1FFAR4XDH | |
| SCHEMBL3382509 | 0.81 | MAOB (0.60) | MAOBXDH | |
| SCHEMBL31114214 | 0.81 | MAOB (0.56) | MAOBFFAR1FFAR4XDH | |
| SCHEMBL6215963 | 0.81 | MAOB (0.60) | MAOBXDH | |
| SCHEMBL8807037 | 0.81 | MAOB (0.60) | MAOBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111971287-B | Macrocyclic compounds as TRK kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | FOCHON BIOSCIENCES, LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| EP-3774812-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | Fochon Pharmaceuticals, Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| CN-111971287-A | Macrocyclic compounds as TRK kinase inhibitors | 重庆复创医药研究有限公司 | 2020-11-20 | — | — | CN | disclosed |
| WO-2019184955-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2019-10-03 | — | — | WO | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | BROUGH STEPHEN (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8044083-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8039639-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039639-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2170848-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| EP-1981851-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | PLK2, ERBB3, DMPK | MAOB 3261/4885FFAR1 2196/4885FFAR4 2001/4885 |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | MAP3K1, MAP3K19, MAP3K20 | MAOB 1294/4885FFAR1 2003/4885FFAR4 2999/4885 |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | PLK2, ERBB3, DMPK | MAOB 3261/4885FFAR1 2196/4885FFAR4 2001/4885 |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | MAP3K19, MAP3K2, MAP3K20 | MAOB 1390/4885FFAR1 2544/4885FFAR4 2974/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | MAOB 954/4885FFAR1 1061/4885FFAR4 1329/4885 |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | CYP3A7, CYP3A5, CYP2C19 | MAOB 1520/4885FFAR1 2248/4885FFAR4 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.